MAPK9, mitogen-activated protein kinase 9, 5601

N. diseases: 115; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.310 Biomarker phenotype BEFREE Alternative promotion and suppression of metastasis by JNK2 governed by its phosphorylation. 28915613 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.310 Therapeutic phenotype CTD_human Knockdown of GAB2 phenocopies knockdown of JNK2 in vivo by reducing tumor growth and metastasis, supporting that JNK2 mediates tumor progression by regulating GAB2. 21779479 2011
CUI: C0005398
Disease: Cholestasis, Extrahepatic
Cholestasis, Extrahepatic 		0.300 Biomarker disease CTD_human Hepatoprotective activities of rosmarinic acid against extrahepatic cholestasis in rats. 28789951 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0040997
Disease: Trigeminal Neuralgia
Trigeminal Neuralgia 		0.300 Biomarker disease CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0393786
Disease: Trigeminal Neuralgia, Idiopathic
Trigeminal Neuralgia, Idiopathic 		0.300 Biomarker disease CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0393787
Disease: Secondary Trigeminal Neuralgia
Secondary Trigeminal Neuralgia 		0.300 Biomarker disease CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0458247
Disease: Allodynia
Allodynia 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751211
Disease: Hyperalgesia, Primary
Hyperalgesia, Primary 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751212
Disease: Hyperalgesia, Secondary
Hyperalgesia, Secondary 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751213
Disease: Tactile Allodynia
Tactile Allodynia 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751214
Disease: Hyperalgesia, Thermal
Hyperalgesia, Thermal 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0032927
Disease: Precancerous Conditions
Precancerous Conditions 		0.300 Biomarker group CTD_human The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. 21317887 2011
CUI: C0282313
Disease: Condition, Preneoplastic
Condition, Preneoplastic 		0.300 Biomarker disease CTD_human The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. 21317887 2011
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury 		0.300 Biomarker disease CTD_human Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. 20302854 2010
CUI: C0022116
Disease: Ischemia
Ischemia 		0.300 Biomarker phenotype CTD_human Wild-type and jnk-2 -/- animals were subjected to hepatic ischemia reperfusion insults in two models: a total hepatic ischemia model involving timed Pringle maneuver, and a partial hepatic ischemia model involving selective occlusion of the portal pedicle supplying the left hepatic lobe. 19667931 2009
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury 		0.300 Biomarker disease CTD_human Jnk-2 -/- animals were protected from hepatic ischemia reperfusion injury. 19667931 2009
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.300 GeneticVariation disease UNIPROT
CUI: C1319315
Disease: Adenocarcinoma of large intestine
Adenocarcinoma of large intestine 		0.300 GeneticVariation disease UNIPROT
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.210 Biomarker disease BEFREE SAPK-JNK pathway performs a significant role in the pathogenesis of type 2 diabetes. 29710525 2018
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.210 Biomarker disease RGD Increased phagocyte-like NADPH oxidase and ROS generation in type 2 diabetic ZDF rat and human islets: role of Rac1-JNK1/2 signaling pathway in mitochondrial dysregulation in the diabetic islet. 21911753 2011
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 AlteredExpression group BEFREE Further suppression of JNK2 and hence c-Jun expression led to the activation of caspase-9 to induce apoptosis and inhibition of tumor growth in xenograft mice model. 30003914 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 Biomarker group BEFREE In contrast, p-JNK2 rose at 2 months of treatment and in tumor tissue. 25724684 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 AlteredExpression group BEFREE In the current study, we found that the expression levels of miR200c in recurrent and metastatic colorectal cancers were significantly lower, whereas the JNK2 expression was higher compared with primary tumors. 25205654 2014